References

  • European Menopause and Andropause Society (EMAS). Vulvovaginal atrophy. 2022.
  • Hamoda H, Moger S, Morris E, et al. Menopause Practice Standards. Post Reproductive Health. 2022;28(3):127-132.
  • Currie H. Women’s Health Concern Factsheet: Vaginal Dryness. British Menopause Society. Last reviewed Oct 2023.
  • Briggs P. Genitourinary Syndrome of Menopause. Post Reproductive Health. 2020; 26(2):111-114.
  • Briggs P. Consensus statement – urogenital atrophy. Post Reproductive Health 2022 28(1):47-50.
  • Portman DJ, Gass ML. Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063–1068.
  • Angelou K, Grigoriadis T, Diakosavvas M, et al. The Genitourinary Syndrome of Menopause. An Overview of the Recent Data. Cureus. 2020;12(4):e7586.
  • Wysocki S, Kingsberg S, Krychman M. Management of vaginal atrophy: implications from the REVIVE survey. Clin Med Insights: Reproductive Health 2014;8:23–30.
  • Hillard T, Abernethy A, Hamoda H, et al. Management of the Menopause. Sixth Edition, 2017. British Menopause Society.
  • Parish SJ, Nappi RE, Krychman ML, et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Women’s Health. 2013;29(5):437-447.
  • Palacios S, Nappi RE, Bruyniks N, et al. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric 2018;21(3):286–291.
  • Kingsberg SA, Wysocki S, Magnus L, et al. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) Survey. J Sex Med 2013;10:1790–1799.
  • Nappi RE, Palacios S, Particco M, et al. The REVIVE (Real Women’s Views of Treatment Options for Menopausal Vaginal Changes) survey in Europe: Country-specific comparisons of postmenopausal women’s perceptions, experiences and needs. Maturitas 2016;91:81–90.
  • Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric. 2014;17(1):3-9.
  • DiBonaventura M, Luo X, Moffatt M, et al. The association between vulvovaginal atrophy symptoms and quality of life among postmenopausal women in the United States and Western Europe. J Women’s Health 2015;24(9):713–722.
  • Mattsson LA and Cullberg G. A Clinical Evaluation of Treatment with Estriol Vaginal Cream versus Suppository in Postmenopausal Women. Acta Obstet Gynecol Scand 1983; 62:397-401.
  • Genazzani AR, Inaudi P, La Rosa R, et al. Oestriol and the menopause: clinical and endocrinological results of vaginal administration. In Fioretti P, Martini L, Melis GB, Yen SSC. Eds. The menopause: clinical, endocrinological and pathophysiological aspects. Proceedings of the Seronia Symposia, Vol.39. Viarregio May 26-28, 1980. London: Academic Press, 1982: 539-50.
  • National Institute for Health and Care Excellence. 2015. Updated December 2019. ‘Menopause: diagnosis and management’.
  • Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews 2016, Issue 8. Art. No.: CD001500.
  • Crandall CJ, Hovey KM, Andrews CA, et al. Breast Cancer, Endometrial Cancer, and Cardiovascular Events in Participants who used Vaginal Estrogen in the Women’s Health initiative Observational Study. Menopause 2018; Jan;25(1):11-20.
  • Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis the worldwide epidemiological evidence. Lancet 2019; 394:1159-1168.
  • MHRA Drug Safety Update. Hormone Replacement Therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping. August 2019.
  • Vooijs GP and Geurts TB. Review of the endometrial safety during intravaginal treatment with estriol. Eur J Obstet Gynecol Reprod Biol 1995; 62(1):101-6.

UK-EST-06-24-00014 June 2024